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nerve injuries was 12.5%. In 1981 we performed the 
same study with a speech therapist. 2'3 This study had 
almost identical results to the present Swedish study 
with a slightly higher incidence of CNI mainly 
because we included injuries to the mandibular 
branch of the facial N. and the Greater Auricular N. 
Cranial nerve injuries, it seems, are here to stay 
following carotid surgery, despite the refinements in 
the technique. The fact that most of them are tempo- 
rary in nature and resolve within 60 days, does not 
mean that they should not be included in perioper- 
ative morbidity rates which should include all events 
within the 30 days period following surgery. 4 Fur, 
thermore, in deciding the real value of endovascular 
alternatives, we should include the issue of nerve 
injuries that D. Bergqvist brought back to our 
attention. 
C. Liapis 
Athens, Greece 
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Quality of Life in Patients with Intermittent 
Claudication 
Sir, 
We read with interest he paper by Khaira et al. 1 but 
question the validity of the method and conclusions. 
The choice of the age/sex matched controls in this 
study may have led to false results: Claudicants are 
well known to have a higher prevalence of cardio- and 
23 cerebrovascular disease ' whereas a surgical waiting 
list for minor procedures (as was used to supply the 
control group) has a large proportion of patients in 
good general health. It is not surprising therefore that 
the claudicant group had an overall worse quality of 
life than the control and although excluding patients 
with "other ailments" increased the significance in the 
difference between the two groups there is no indica- 
tion what these ailments were. 
The authors state that "restriction in mobility" was 
the underlying cause of the difference between claudi- 
cants and controls. It cannot however, be assumed that 
the restriction in mobility was due to claudication and 
not, for example, stroke or ischaemic heart disease. 
We agree wholeheartedly with the call for pro- 
spective controlled trials comparing quality of life 
measurement with traditional efficacy/safety parame- 
ters: Generic quality of life instruments are useful as 
outcome measure if used for pre- and postoperative 
comparisons. It must be remembered however that a 
generic instrument (such as the Nottingham Health 
profile) can only assess quality of life per se, not the 
impact of claudication on quality of life, because 
generic instruments do not differentiate between the 
relative effects of claudication and the coexistent 
disorders which are so frequent in these patients. If 
clinicians truly wish to measure the impact of inter- 
mittent claudication on quality of life and use this 
measurement to influence the management of their 
patients it is essential that a disease-specific instru- 
ment is used otherwise the quality of life may be 
underestimated and the need for intervention overes- 
timated. 
G. Hicken and M. Ameli 
Toronto, Canada 
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Author's Reply 
Sir, 
We thank Messrs Hicken and Amali for their interest 
in our paper. Our aim was to select a control 
population which had undergone the same pattern of 
referral (i.e. from GP to hospital specialist) as the 
patients with intermittent claudication. Previous pub- 
lications on this subject had used inappropriate 
controls. In our questionnaire we enquired about 
problems such as angina, shortness of breath on 
exertion, stroke, previous heart attacks, and arthritis 
(i.e. conditions that would limit mobility). We found 
that the two groups were well matched for these 
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"other ailments" and, therefore, cannot agree that the 
control group contains a large proportion of patients 
in good health simply because they are on a waiting 
list for minor procedures. 
We agree that generic questionnaires such as the 
NHP may underestimate he quality of life and that 
the effect of additional ailments could confound 
attempts at assessing the impact of claudication on 
quality of life (as considered in the 'Discussion' section 
of the paper). We are, however, not aware of a 
validated disease specific questionrkaire for inter- 
mittent claudication. 
H. S. Khaira 
Sutton Coldfield, U.K. 
Spinal Cord Stimulation 
Sir, 
It has been suggested uring the last decades that SCS 
improves limb salvage and reduces tissue loss in 
patients with non-reconstructable critical imb ischae- 
mia. However, the demonstration of a limb saving 
effect requires randomised, controlled prospective 
studies. The study of Jivegard et al. is one of the first 
multicentre studies evaluating the hypothesis that SCS 
improves limb salvage in patients with non-recon- 
structable critical limb ischaemia. ~ 
Patient selection was based on the criteria published 
in the Second European Consensus Document on 
2 Chronic Critical Leg Ischaemia. Analysing the data 
listed in Table 2, 21 (84%) of the 25 patients in the SCS- 
group, and 24 (92%) of the 26 patients in the control 
group had critical imb ischaemia. The clinical stage of 
the remaining four patients in the SCS-group (16%) 
and two patients in the control group (8%), is not clear 
and should be discussed. The analysis of this study 
was by "intention to treat", and every patient rando- 
mised to SCS was analysed, however three patients 
(12%) were never implanted. At 18 months the 
investigators found a 17% difference in limb salvage, 
62% with SCS and 45% without. This result was not 
statistically significant, probably due to the small 
number of patients and the fact that patient selection 
was only based upon macrocirculatory parameters. 
During the last years more than 7000 stimulators have 
been implanted across Europe for "peripheral vas- 
cular disease". On the other hand the 1994 European 
multicentre randomised study sought over 3000 
patients and was stopped due to problems with 
patient enrollment. This shows clearly that patient 
selection and definition of "non-reconstructability" is 
the key problem. However, we need a strict definition 
of the non-reconstructable patient, in order to compare 
and interpret he published ata. 
We know from our clinical experience with SCS that 
many patients with critical limb ischaemia will not 
respond to stimulation therapy. Only the use of very 
strict selection criteria, based upon morphology and 
function of the microcirculation can reduce the num- 
ber of non-responders. The prognostic value of micro- 
circulatory parameters (e.g. TcP02), regarding ulcer 
healing under stimulation has been shown in different 
studies. 3'4 This was also studied in the 120 patients of 
the Dutch multicentre prospective randomised study 
and it seemed that initial TcP02 and the number of 
perfused capillaries were predictors of limb salvage. 5 
It is then also obvious that objective methods for the 
study of the microcirculation should be available at 
those institutions performing stimulation for vascular 
indications. 
In the evaluation of stimulation procedures, ther- 
apeutic success is often equated with pain relief or 
pain reduction. However, therapeutic success is not 
synonymous with pain reduction. 6 Intake of analge- 
sics, functional improvement, quality of life, cost 
effectiveness calculations and adverse vents are also 
important aspects of therapeutic outcome. Therefore, 
the same concepts as in pain research should be 
adopted and assessment of the different parameters 
should be performed by an independent third party. 
The major disadvantages of the visual analogue scale 
is its assumption that pain is a unidimensional 
experience. Therefore, the use of other methods, like 
the McGill Pain Questionnaire is recommended. 7 
The following conclusions can be made: (1) spinal 
cord stimulation provides a significant long-term pain 
relief, and improves ignificantly ulcer healing due to 
effects on the nutritional skin blood flow, (2) effects on 
limb survival are not proven. Further multicentre 
clinical research is needed to evaluate the exact place 
of spinal cord stimulation in the treatment of critical 
limb ischaemia. Better coordination between the dif- 
ferent SCS-centres i mandatory. Studies investigating 
the cost effectiveness of stimulation are also 
necessary. 
L. Claeys 
Vienna, Austria 
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